<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598439</url>
  </required_header>
  <id_info>
    <org_study_id>MCL10218</org_study_id>
    <nct_id>NCT03598439</nct_id>
  </id_info>
  <brief_title>Randomized Influenza Vaccine Evaluation of Immune Response</brief_title>
  <acronym>RIVER</acronym>
  <official_title>Randomized Open-Label Trial to Compare Immunogenicity of Egg-Based and Non-Egg Based Quadrivalent Influenza Vaccines Among Adults 18-64 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2018-19 and 2019-20)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marshfield Clinic Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Marshfield Clinic Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Licensed influenza vaccines are manufactured with a variety of technologies. The majority are
      split, inactivated vaccines derived from egg-adapted, high growth reassortant viruses. Two US
      licensed products do not use egg-adapted viruses: Flucelvax (mammalian cell culture) and
      FluBlok (recombinant). There is increasing evidence that egg propagation induces virus
      mutations that impair the immune responses to circulating viruses. However, the impact of
      egg-propagation on clinical vaccine effectiveness is uncertain, and there is no preferential
      recommendation for any specific influenza vaccine product or technology. A direct comparison
      of serologic response to egg based and non-egg based vaccines in adults has not been
      performed. This randomized trial will compare serologic responses to the egg- and non-egg
      A(H3N2) vaccine component. The study cohort will be followed for two influenza seasons to
      evaluate sequential vaccination effects on immune response.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-vaccination titer</measure>
    <time_frame>28 days</time_frame>
    <description>geometric mean titers (as measured by microneutralization) to cell-grown A(H3N2) vaccine reference virus</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Recombinant (RIV4) Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of licensed recombinant influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cell-culture (ccIIV4) Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of licensed cell-culture influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard (IIV4) Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of licensed standard influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard IIV4</intervention_name>
    <description>Standard inactivated influenza vaccine</description>
    <arm_group_label>Standard (IIV4) Influenza Vaccine</arm_group_label>
    <other_name>Flulaval Quadrivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant</intervention_name>
    <description>Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector</description>
    <arm_group_label>Recombinant (RIV4) Influenza Vaccine</arm_group_label>
    <other_name>FluBlok Quadrivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell-culture</intervention_name>
    <description>inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.</description>
    <arm_group_label>Cell-culture (ccIIV4) Influenza Vaccine</arm_group_label>
    <other_name>Flucelvax Quadrivalent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-64 years

          -  Marshfield Clinic patients living in or around Marshfield, Wisconsin since July 2015

          -  Willing and able to give informed consent and comply with study requirements

        Exclusion Criteria:

          -  Receipt of 2018-19 influenza vaccine prior to study enrollment

          -  Known to be pregnant at the time of enrollment

          -  Current participation or plans to participate in another clinical trial involving an
             experimental agent

          -  Presence of a contraindication to influenza vaccination

          -  Plans to relocate outside the geographic location in the next two years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marshfield Clinic Research Foundation</investigator_affiliation>
    <investigator_full_name>Huong McLean, PhD</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>influenza vaccine</keyword>
  <keyword>adults</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

